Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate TuHURA Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding TuHURA Biosciences, Inc.’s stock price such as:

• TuHURA Biosciences, Inc.’s current stock price and volume
• Why TuHURA Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for HURA from analysts
• HURA’s stock price momentum as measured by its relative strength

About TuHURA Biosciences, Inc. (HURA)

Before we jump into TuHURA Biosciences, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Want to learn more about TuHURA Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about TuHURA Biosciences, Inc..

TuHURA Biosciences, Inc.’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, TuHURA Biosciences, Inc.’s stock price was $2.090.

TuHURA Biosciences, Inc. is up 7.73% from its previous closing price of $1.940.

During the last market session, TuHURA Biosciences, Inc.’s stock traded between $1.940 and $2.160. Currently, there are approximately 50.67 million shares outstanding for TuHURA Biosciences, Inc..

TuHURA Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

TuHURA Biosciences, Inc. Stock Price History

TuHURA Biosciences, Inc.’s (HURA) price is currently down 18.04% so far this month.

During the month of November, TuHURA Biosciences, Inc.’s stock price has reached a high of $2.600 and a low of $1.560.

Over the last year, TuHURA Biosciences, Inc. has hit prices as high as $7.200 and as low as $1.560. Year to date, TuHURA Biosciences, Inc.’s stock is down 48.9%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused TuHURA Biosciences, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 25, 2025, there were 0 analysts who downgraded TuHURA Biosciences, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate TuHURA Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on TuHURA Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about TuHURA Biosciences, Inc. (HURA) by visiting AAII Stock Evaluator.

Relative Price Strength of TuHURA Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 25, 2025, TuHURA Biosciences, Inc. has a weighted four-quarter relative price strength of -18.80%, which translates to a Momentum Score of 11 and is considered to be Very Weak.

Want to learn more about how TuHURA Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

TuHURA Biosciences, Inc. Stock Price: Bottom Line

As of November 26, 2025, TuHURA Biosciences, Inc.’s stock price is $2.090, which is up 7.73% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like TuHURA Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.